4D Molecular Therapeutics, Inc. (FDMT)
NASDAQ: FDMT · Real-Time Price · USD
7.55
-0.06 (-0.79%)
At close: Jan 16, 2026, 4:00 PM EST
7.76
+0.21 (2.77%)
After-hours: Jan 16, 2026, 7:35 PM EST
4D Molecular Therapeutics Employees
4D Molecular Therapeutics had 227 employees as of December 31, 2024. The number of employees increased by 80 or 54.42% compared to the previous year.
Employees
227
Change (1Y)
80
Growth (1Y)
54.42%
Revenue / Employee
$529
Profits / Employee
-$921,485
Market Cap
431.37M
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 227 | 80 | 54.42% |
| Dec 31, 2023 | 147 | 7 | 5.00% |
| Dec 31, 2022 | 140 | 16 | 12.90% |
| Dec 31, 2021 | 124 | 41 | 49.40% |
| Dec 31, 2020 | 83 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 400,000 |
| Johnson & Johnson | 138,100 |
| Thermo Fisher Scientific | 125,000 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 92,900 |
| Novo Nordisk | 77,349 |
| Novartis AG | 75,883 |
| Merck & Co. | 75,000 |
FDMT News
- 6 hours ago - 4DMT Announces New Employment Inducement Grants - GlobeNewsWire
- 3 days ago - 4D Molecular Therapeutics, Inc. (FDMT) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript - Seeking Alpha
- 10 days ago - 4DMT Provides Company Update and Anticipated Development Milestones for 2026 - GlobeNewsWire
- 4 weeks ago - 4D Molecular Therapeutics, Inc. (FDMT) Discusses Interim Phase I Data From AEROW Trial in Cystic Fibrosis and Platform Potential Transcript - Seeking Alpha
- 4 weeks ago - 4DMT Announces Positive Interim Clinical Data from 4D-710 AEROW Phase 1 Clinical Trial in Cystic Fibrosis Lung Disease - GlobeNewsWire
- 5 weeks ago - 4DMT Announces New Employment Inducement Grants - GlobeNewsWire
- 5 weeks ago - 4DMT to Present at the 44th Annual J.P. Morgan Healthcare Conference - GlobeNewsWire
- 2 months ago - 4D Molecular Therapeutics, Inc. (FDMT) Presents at Jefferies London Healthcare Conference 2025 Transcript - Seeking Alpha